Forbion is proud to announce the proposed election of its General Partner Nanna Lüneborg to biotech company BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV). BioInvent is a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy. The election will take place at the Extraordinary General Meeting (“EGM”) on July 12, 2022.
Forbion notified the financial market that its Forbion Growth Opportunities Fund I has reached a holding of over 5% of the shares and votes in the company on 8 June 2022. BioInvent’s nomination committee, consisting of Laura Feinleib (Redmile Group, LLC), Erik Esveld (van HerkInvestments B.V.), Vincent Ossipow (Omega Funds, LP) and the Chairman of the Board, Leonard Kruimer, now proposes that the Board of Directors of BioInvent will be increased by two members and that Natalie Berner and Nanna Lüneborg are elected as new Board members of BioInvent.
“We are impressed with the innovation and scientific rigour that underpins the platform and pipeline of BioInvent, and the team has done an excellent job to deliver multiple novel programs into the clinic. We look forward to the option of working with the Board of Directors and management team to build a successful oncology company by making better therapeutic options available to cancer patients,” commented Nanna Lüneborg, General Partner at Forbion.
Nanna Lüneborg, is General Partner at Forbion since September 2021. She has previously been a partner at Novo Ventures, one of the largest healthcare investors globally, and a key member of the European deal team focusing on late-stage biopharma investments across Europe. Nanna began her career in venture capital at Apposite Capital. She holds an MBA from the University of Cambridge, a PhD in Neuroscience from University College London, and a BA in Physiology and Psychology from the University of Oxford. She has previously served on the Board of Directors of publicly traded and privately held companies, including Lava Therapeutics, Numab, ReViral, NBE Therapeutics, ObsEva, IO Biotech, Inventiva, Orphazyme, NodThera, MinervaX, and Stargazer. Nanna Lüneborg is assessed to be independent in relation to the company, the executive management and major shareholders.